Leaders at the Centers for Medicare and Medicaid Services (CMS) recently published updated data with the purpose of improving the transparency of the current Medicare program.

Leaders at the U.S. Food and Drug Administration (FDA) recently granted approval of Probuphine, which is the first buprenorphine implant that is designed to treat opioid dependence.

Bristol-Myers Squibb recently responded to a report from the Institute for Clinical and Economic Review (ICER) about determining value measurements for patients in the health industry.

Axumin, a radioactive diagnostic agent for injections, recently received approval from the U.S. Food and Drug Administration (FDA), as the new technology may be useful in detecting recurrent prostate cancer.

UnitedHealthcare, the nation’s largest health insurer, has quit the Illinois Obamacare exchange, a move that will leave consumers in its wake searching among fewer policy choices, while seeing higher costs and less competition from other insurers.

Officials with the U.S. Food and Drug Administration (FDA) recently approved of Zinbryta (daclizumab) to treat adult patients who have relapsing variations of multiple sclerosis (MS).

The Committee for Medicine Products for Human Use (CHMP) branch of the European Medicines Agencies (EMA) recently granted a positive opinion of Zepatier, a Merck product.

As new details continue to emerge from the investigation into the Obama administration’s decision to spend billions of dollars on the ACA's Basic Health Program (BHP) without a congressional appropriation, the pressure from Congress on the U.S. Department of Health and Human Services continues to mount.

Leaders at the National Coalition of Health Care (NCHC) recently praised the updated additions of the Hospital Readmission Reduction Program (HRRP) from Medicare.

Researchers from the University of California San Francisco Medical Center recently stated that, in honor of World MS Day, they want to design more therapies that will help patients with multiple sclerosis (MS) achieve greater independence.

Leaders at the U.S. Food and Drug Administration (FDA) recently granted approval to CSL Behring’s new Afstyla recombinant factor VIII single chain therapy, designed to treat hemophilia A.

The American Academy of Family Physicians recently released numbers from a Centers for Disease Control and Prevention (CDC) report that provide information related to the Zika virus and pregnant women.

AbbVie, a worldwide biopharmaceutical company, recently announced that officials at the European Commission (EC) have approved Imbruvica to be used as a first-line treatment option for chronic lymphocytic leukemia (CLL).

Approximately 37,000 Coventry health insurance enrollees in Iowa may experience premium hikes that average 23 percent in 2017.

BioMarin Pharmaceutical Inc. recently announced its decision to withdraw its Marketing Authorization Application (MAA) for Kyndrisa (drisapersen) from Europe after holding the May 2016 Committee for Medicines Agency (EMA) meeting.

Purdue Pharma LP recently announced that it has entered into a patent agreement with Acura Pharmaceuticals Inc. and Egalet Corporation to settle a variety of patent claims.

The American Academy of Family Physicians (AAFP) first developed member interest groups (MIGs) in 2014, and these groups have shown a steady growth of interest since their inception.

The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to combine Ocaliva with ursodeoxycholic acid (UDCA) to treat primary biliary cholangitis (PBC).

The American Heart Association Rapid Access Journal Report recently published a study showing that middle-aged African-Americans have higher death risks from strokes than white Americans because they have more strokes, not because they receive different care after having a stroke.

AstraZeneca recently announced that it has finished its U.S. licensing agreement for the exclusive U.S. rights to Zurampic, also called lesinurad, as well as the fixed-dose lesinurad and allopurinol combination from Ironwood Pharmaceuticals.